SRPT vs TSHA
SRPT: Sarepta Therapeutics is a leader in genetic medicine, specializing in innovative RNA-targeted and gene therapies to treat rare neuromuscular diseases like Duchenne muscular dystrophy. TSHA: Taysha Gene Therapies is a clinical-stage biotechnology company developing AAV-based gene therapies for rare, monogenic central nervous system disorders.
Side-by-side fundamentals
| Metric | SRPT | TSHA | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $18.21 | $4.43 | |
| Market cap | $1.9B | $1.4B | |
| Net margin FY2025, SEC XBRL | -32.5% | -1115.3% | SRPT higher |
| Operating margin FY2025, SEC XBRL | -31.8% | -1130.6% | SRPT higher |
| ROE FY2025, SEC XBRL | -62.5% | -44.1% | TSHA higher |
| ROA FY2025, SEC XBRL | -21.3% | -31.7% | SRPT higher |
| Debt / equity as of 2026-09-02 | 0.55 | 0.23 | TSHA lower |
| Revenue growth (YoY) as of 2026-09-02 | -20.4% | +3.4% | TSHA higher |
| Revenue CAGR (3y) SEC XBRL | +33.1% | +57.5% | TSHA higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.56 | 1.29 | |
| 1-year return as of 2026-10-08 close | -22.1% | -12.5% | TSHA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.